Top Breast Cancer Research at ASCO 2026

Eleonora Teplinsky discusses the OPTIMA and ASCENT-04 studies and offers insights on GLP-1 medicines and cancer.

Published on June 2, 2026

https://images.ctfassets.net/zzorm7zihro2/5odoao1FQlYGvgOzTRFDXC/3d4f7250a1e32b46f2ba0c8021fa9cb3/ASCO_Generic_01_2466x1644.jpg
00:00
00:00

Eleonora Teplinsky, MD, is the head of breast and gynecologic medical oncology and Valley-Mount Sinai Comprehensive Cancer Center in Paramus, New Jersey, as well as an ASCO breast cancer expert. She explained the most compelling research results on breast cancer presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Listen to the episode to hear Dr. Teplinsky explain:

  • the importance of the OPTIMA study, as well as her caveats about the results

  • the latest results from the ASCENT-04 study

  • what progression-free survival 2 (PFS2) is and how it helps doctors decide which treatments should be given first

  • what we do and don’t know about GLP-1 medicines and cancer

 
About the guests
 
Eleonora Teplinsky headshot
Eleonora Teplinsky, MD

Eleonora Teplinsky, MD, is a board-certified medical oncologist specializing in breast and gynecologic oncology. She is head of breast and gynecologic medical oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, NJ, and a clinical assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York.

 

This podcast episode is made possible, in part, by a grant from Lilly.

 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate